Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 1, 2010, Pages 181-186

  Verkoczy, Laurent ^a,b   Diaz, Marilyn ^c   Holl, T Matt ^b   Ouyang, Ying Bin ^d   Bouton Verville, Hilary ^a,b   Alam, S Munir ^a,b   Liao, Hua Xin ^a,b   Kelsoe, Garnett ^b   Haynes, Barton F ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d Xenogen Biosciences   (United States)

Author keywords

2F5; Autoantigens; B cell development; Broadly neutralizing antibodies

Indexed keywords

AUTOANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL CYCLE ARREST; CELL LOSS; CELL MATURATION; CONTROLLED STUDY; FEMALE; GENE INSERTION; GENE LOCUS; GENE REARRANGEMENT; GENE TARGETING; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEUTRALIZING; AUTOANTIGENS; B-LYMPHOCYTES; CELL LINE; FEMALE; GENE KNOCK-IN TECHNIQUES; GENE REARRANGEMENT; HIV-1; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; SPLEEN;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS;

EID: 76249083814     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912914107     Document Type: Article

References (47)

1. Letvin NL, et al. (2006) Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-1533.
2. Buchbinder SP, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
3. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951-954.
4. Hessell AJ, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433.
5. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210.
6. Burton DR, Stanfield RL, Wilson IA (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102:14943-14948.
7. Haynes BF, Montefiori DC (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 5:579-595.
8. Haynes BF, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
9. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM (2005) Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum Antibodies 14:59-67.
10. Alam SM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178:4424-4435.
11. Sánchez-Martínez S, et al. (2006) Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett 580: 2395-2399.
12. Scherer EM, Zwick MB, Teyton L, Burton DR (2007) Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-2139.
13. Muster T, et al. (1994) Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68:4031-4034.
14. Muster T, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642-6647.
15. Crouzier R, Martin T, Pasquali JL (1995) Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors. J Immunol 154: 4526-4535.
16. Ichiyoshi Y, Casali P (1994) Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med 180:885-895.
17. Radic MZ, Weigert M (1994) Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 12:487-520.
18. Cardoso RM, et al. (2007) Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 365:1533-1544.
19. Zhou T, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
20. Chen C, Prak EL, Weigert M (1997) Editing disease-associated autoantibodies. Immunity 6:97-105.
21. Chen C, et al. (1995) The site and stage of anti-DNA B-cell deletion. Nature 373: 252-255.
22. Chen C, et al. (1994) Deletion and editing of B cells that express antibodies to DNA. J Immunol 152:1970-1982.
23. Erikson J, et al. (1991) Expression of anti-DNA immunoglobulin transgenes in nonautoimmune mice. Nature 349:331-334.
24. Li H, Jiang Y, Prak EL, Radic M, Weigert M (2001) Editors and editing of anti-DNA receptors. Immunity 15:947-957.
25. Li Y, Li H, Weigert M (2002) Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med 195:181-188.
26. Chen C, et al. (2006) Selection of anti-double-stranded DNA B cells in autoimmune MRL-lpr/lpr mice. J Immunol 176:5183-5190.
27. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K (1991) Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 173:1213-1225.
28. Sekiguchi DR, et al. (2006) Development and selection of edited B cells in B6.56R mice. J Immunol 176:6879-6887.
29. Goodnow CC, Brink R, Adams E (1991) Breakdown of self-tolerance in anergic B lymphocytes. Nature 352:532-536.
30. Goodnow CC, et al. (1988) Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334:676-682.
31. Allman D, et al. (2001) Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 167:6834-6840.
32. Simek MD, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 83:7337-7348.
33. Shen X, et al. (2009) In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 83:3617-3625.
34. Meffre E, et al. (2001) Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 108:879-886.
35. Zou X, et al. (2007) Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice. J Exp Med 204:3271-3283.
36. Kiefer K, et al. (2008) Antigen receptor editing in anti-DNA transitional B cells deficient for surface IgM. J Immunol 180:6094-6106.
37. Nakajima PB, Kiefer K, Price A, Bosma GC, Bosma MJ (2009) Two distinct populations of H chain-edited B cells show differential surrogate L chain dependence. J Immunol 182:3583-3596.
38. Culton DA, et al. (2006) Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol 176:790-802.
39. Ferry H, Jones M, Vaux DJ, Roberts IS, Cornall RJ (2003) The cellular location of selfantigen determines the positive and negative selection of autoreactive B cells. J Exp Med 198:1415-1425.
40. Chen C, Nagy Z, Prak EL, Weigert M (1995) Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity 3:747-755.
41. Shlomchik MJ (2008) Sites and stages of autoreactive B cell activation and regulation. Immunity 28:18-28.
42. Han S, Zheng B, Dal Porto J, Kelsoe G (1995) In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. J Exp Med 182:1635-1644.
43. Alam SM, et al. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA, in press.
44. de Groot PG, Derksen RH (2005) Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3:1854-1860.
45. Vcelar B, et al. (2007) Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21: 2161-2170.
46. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100: 4144-4149.
47. Wei X, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.